 Connection
Syed Naqvi to Aged
This is a "connection" page, showing publications Syed Naqvi has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.184 |
|
|
|
-
Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K. Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. J Immunother Cancer. 2026 May 04; 14(5).
Score: 0.023
-
Cheema H, Shrestha A, Naqvi S, Muttineni S, Dronavalli S, Alrawabdeh J, Alzu'bi M, Schinke CD, Thanendrarajan S, Shaughnessy JD, Zhan F, Zangari M, van Rhee F, Hadidi SA. Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients. Blood Cancer J. 2026 Mar 31; 16(1).
Score: 0.023
-
Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin GR. Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review. Br J Haematol. 2026 Mar; 208(3):829-836.
Score: 0.022
-
DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters MWJM, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Olofsson Bagge R, Zager JS. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. Cancer. 2025 Jan 01; 131(1):e35636.
Score: 0.021
-
Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. Lung Cancer. 2024 Dec; 198:107999.
Score: 0.021
-
Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, Mullinax JE, Zager JS. Isolated Limb Infusion for Limb-Threatening Sarcomas. Ann Surg Oncol. 2024 Dec; 31(13):9272-9280.
Score: 0.020
-
Carr MJ, Sun J, DePalo D, Rothermel LD, Song Y, Straker RJ, Baecher K, Louie RJ, Stahlie EHA, Wright GP, Naqvi SMH, Kim Y, Sarnaik AA, Karakousis GC, Lowe MC, Delman KA, van Akkooi ACJ, Ollila DW, Collichio F, Zager JS. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Ann Surg Oncol. 2022 Feb; 29(2):791-801.
Score: 0.017
-
Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Br J Haematol. 2019 03; 184(5):735-743.
Score: 0.014
-
Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 01; 59(1):59-68.
Score: 0.012
-
Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, Bhati R, Hardmann D, Sileno S, O'Donoghue C, Perez M, Naqvi SM, Chen YA, Gonzalez RJ, Zager JS. Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. J Am Coll Surg. 2017 Apr; 224(4):635-642.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|